Please login to the form below

Not currently logged in
Email:
Password:

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements
EU flag

Three new medicines and six licence extensions have all been recommended for European approval from the CHMP.

The CHMP, the drug safety and efficacy arm of the EMA, has recommended approval for Otsuka's Jinarc (tolvaptan) for the treatment of patients with autosomal dominant polycystic kidney disease (ADPKD), and Sanofi's new insulin Toujeo, the follow up to its blockbuster insulin Lantus.

The CHMP has also recommended granting a conditional marketing authorisation for Novartis' Zykadia (ceritinib).

Specifically, the licence for the drug is for non-small cell lung cancer patients expressing the anaplastic lymphoma kinase (ALK) mutation.

It is designed to treat patients at an advanced stage and in a second-line setting, after patients have already been treated with Pfizer's established ALK lung cancer treatment Xalkori (crizotinib).

The CHMP also made six recommendations on extensions of therapeutic indication.

This includes Adenuric, blockbuster oncology treatment Avastin (bevacizumab) from Roche; AbbVie's auto-inflammatory drug Humira (adalimumab), Menarini's gout drug Adenuric, (febuxostat), the rare disease drug for kidney disease Soliris (eculizumab), BMS's HIV pill Sustiva (efavirenz), and finally Amgen's cancer medicine Vectibix (panitumumab).

Article by
Ben Adams

3rd March 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics